ArticlePediatric nephrology (Berlin, Germany)2025
Risk profile of promoters and inhibitors of kidney stone formation in paediatric inflammatory bowel disease.
Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Critique on "Risk profile of promoters and inhibitors of kidney stone formation in paediatric inflammatory bowel disease".Pediatric nephrology (Berlin, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNephrolithiasis is a well-known extraintestinal complication of adult inflammatory bowel disease (IBD), mainly attributed to hyperoxaluria. In contrast, data for paediatric IBD are limited. The objective of this study was to evaluate renal stone risk in children and adolescents with IBD by analysing urine composition concerning stone promoters and inhibitors and their possible influencing factors.
methodsIn this cross-sectional study, the 24-h urine composition of 107 children and adolescents with surgically untreated IBD compared to 27 healthy controls was analysed regarding the risk of kidney stone development, including an evaluation using the CMC index [(citrate × magnesium)/calcium]. Disease activity, as assessed by the Paediatric Crohn Disease Activity Index (PCDAI), Paediatric Ulcerative Colitis Activity Index (PUCAI), and faecal calprotectin (FC) was investigated as influencing factor.
resultsStone inhibitors were lower in active IBD than in remission (citrate, P = 0.001; magnesium, P = 0.004). The CMC index was also decreased in active disease (P = 0.001), indicating increased urinary lithogenicity in these children. PCDAI and PUCAI were predictors of the CMC index. This proved relevant in the groups IBD, IBD with active disease (B = - 0.072, P = 0.029, adjusted R
conclusionsMonitoring urine for lithogenic alterations and calculating CMC index in paediatric active IBD could contribute to identifying at-risk patients for later nephrolithiasis early, although childhood stone prevalence is low.
Indexed as
Identifiers
40560272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.